Bazinaprine (SR-95,191) is an experimental drug candidate. It is a
monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of
depression. The drug strongly inhibits type A
monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible
in vivo, but not
in vitro.[1] In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.[2]
^Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K (April 1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44.
doi:
10.1111/j.1471-4159.1988.tb10584.x.
PMID3346672.
S2CID12521641.